Testing a new blood test to detect multiple types of cancer early.
Official title: Administrative Supplement: CSRN Vanguard Study
Funded at Univ of North Carolina Chapel Hill · NIH-11267372 · Data updated 2026-11-12
This study is looking to create a new blood test that can help find different types of cancer early, especially for those that don’t have good screening options yet, and it’s inviting people from the University of North Carolina's cancer center to see how well this test works for everyone, including those who are often overlooked in research.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | February 15, 2024 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $544,248 |
| NIH project number | 3UG1CA286949-02S1 |
| Project ID | NIH-11267372 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals from diverse backgrounds, particularly those in historically underrepresented populations, who are at risk for various types of cancer.
✕Less likely to help
Patients who are not at risk for cancer or those who have already been diagnosed with cancer may not benefit from this research.
What this research studies
This research focuses on developing multi-cancer detection tests (MCDs) that can identify various cancer types from a single blood sample. By utilizing advances in cell-free DNA detection, the study aims to improve early cancer detection, particularly for cancers that currently lack effective screening methods. The research will involve a feasibility study to evaluate how well these tests can be implemented in diverse populations, especially among historically underrepresented groups. Participants will be recruited from the University of North Carolina's cancer center to assess the risks and benefits of these innovative screening technologies.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection of multiple cancers, potentially reducing mortality rates.
How similar studies have gone: Other research has shown promise in using cell-free DNA for cancer detection, indicating that this approach could be effective.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Reuland, Daniel S. — Univ of North Carolina Chapel Hill
- Study coordinator: Reuland, Daniel S.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.